title: [Pharmakokinetics of hydroxy-urea. Therapy of acute myeoblastic leukemias using synchronization and recruitment effects (author' transl)].
abstract: By a plasma-concentration of hydroxy-urea (HU) higher than 0.5-2.2x10(-4)M the DNA-synthesis in leukemia cells was blocked reversibly in 9 patients. The plasma half-time of HU varied between 120 and 198 min. To synchronize leukemic cell populations the DNS-synthesis was blocked over a period of 36 hours by maintaining the HU-concentration above the critical lower level. In a second phase-specific therapeutic step cytosine-arabinoside (AraC) was given 4 times in a dose of 1 mg/kg each. A recruitment after the application of AarC made more cells available for the next following synchronization step. 4 acute myeloblastic leukemias with high peripheral cell counts were treated according to this schedule. One patient is still in complete remission for now 14 month. This synchronization/recruitment schedule seems to be successful in acute myeloblastic leukemias with high proliferation rates measured by biochemical and cytokinetic methods.
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002455:Cell Division / Q000187:drug effects*; D003561:Cytarabine / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000096:biosynthesis; D006207:Half-Life; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000097:blood*; D007700:Kinetics; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D013997:Time Factors
chemical_list: D004273:DNA, Neoplasm; D003561:Cytarabine; D006918:Hydroxyurea
vernacular_title: Zur Pharmakokinetik von Hydroxy-Harnstoff und seine Anwendung bei der Therapie von akuten myeloischen Leukämien u